Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective

M. Kacer, L. Kielberger, M. Bouda, T. Reischig,

. 2015 ; 17 (3) : 334-41. [pub] 20150526

Jazyk angličtina Země Dánsko

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17024251

INTRODUCTION: Valganciclovir (vGCV) and valacyclovir (vACV) are used in cytomegalovirus (CMV) prophylaxis in renal transplant recipients. The aim of this study was to compare the economic impact of both regimens during 1-year follow-up. METHODS: A total of 117 renal transplant recipients at risk for CMV were randomized to 3-month prophylaxis either with vGCV (900 mg/day, n = 60) or vACV (8 g/day, n = 57) and their data used in a pharmacoeconomic analysis. The pharmacoeconomic evaluation involved all direct CMV-related expenses in the first year after transplantation. Sensitivity analysis was employed to examine the effects of various prices of antiviral drugs and diagnostic procedures on overall CMV-related costs. Simulation of the more expensive US healthcare perspective was performed, and a scenario involving costs of acute rejection (AR) was examined. RESULTS: Overall CMV-related costs were significantly lower in the vACV arm; median United States dollars (USD) 3473 (3108-3745) vs. USD 5810 (4409-6757; P < 0.001) per patient, respectively. Our data showed that the critical determinant of the major disparity between the prophylactic regimens was the prophylaxis price. Median cost of prophylaxis in the vACV group was USD 1729 (1527-2173) compared to USD 3968 (2683-4857) in the vGCV group (P < 0.001). In sensitivity analysis of the overall CMV-related costs, the least and the most expensive pharmacotherapy and diagnostic scenarios were used; nevertheless, the vACV arm remained markedly less expensive. Simulation considering the higher physician/nurse and hospitalization fees of the US healthcare system and the scenario including expenditure associated with AR episodes also favored vACV. CONCLUSION: VACV prophylaxis for CMV is associated with a significant 44% lower cost than vGCV at the first year after renal transplantation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17024251
003      
CZ-PrNML
005      
20250402092214.0
007      
ta
008      
170720s2015 dk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/tid.12383 $2 doi
035    __
$a (PubMed)25824586
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a dk
100    1_
$a Kacer, M $u Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
245    10
$a Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective / $c M. Kacer, L. Kielberger, M. Bouda, T. Reischig,
520    9_
$a INTRODUCTION: Valganciclovir (vGCV) and valacyclovir (vACV) are used in cytomegalovirus (CMV) prophylaxis in renal transplant recipients. The aim of this study was to compare the economic impact of both regimens during 1-year follow-up. METHODS: A total of 117 renal transplant recipients at risk for CMV were randomized to 3-month prophylaxis either with vGCV (900 mg/day, n = 60) or vACV (8 g/day, n = 57) and their data used in a pharmacoeconomic analysis. The pharmacoeconomic evaluation involved all direct CMV-related expenses in the first year after transplantation. Sensitivity analysis was employed to examine the effects of various prices of antiviral drugs and diagnostic procedures on overall CMV-related costs. Simulation of the more expensive US healthcare perspective was performed, and a scenario involving costs of acute rejection (AR) was examined. RESULTS: Overall CMV-related costs were significantly lower in the vACV arm; median United States dollars (USD) 3473 (3108-3745) vs. USD 5810 (4409-6757; P < 0.001) per patient, respectively. Our data showed that the critical determinant of the major disparity between the prophylactic regimens was the prophylaxis price. Median cost of prophylaxis in the vACV group was USD 1729 (1527-2173) compared to USD 3968 (2683-4857) in the vGCV group (P < 0.001). In sensitivity analysis of the overall CMV-related costs, the least and the most expensive pharmacotherapy and diagnostic scenarios were used; nevertheless, the vACV arm remained markedly less expensive. Simulation considering the higher physician/nurse and hospitalization fees of the US healthcare system and the scenario including expenditure associated with AR episodes also favored vACV. CONCLUSION: VACV prophylaxis for CMV is associated with a significant 44% lower cost than vGCV at the first year after renal transplantation.
650    _2
$a acyklovir $x aplikace a dávkování $x analogy a deriváty $x ekonomika $7 D000212
650    _2
$a dospělí $7 D000328
650    _2
$a antivirové látky $x aplikace a dávkování $x ekonomika $7 D000998
650    _2
$a Cytomegalovirus $x účinky léků $7 D003587
650    _2
$a cytomegalovirové infekce $x ekonomika $x prevence a kontrola $7 D003586
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a ganciklovir $x aplikace a dávkování $x analogy a deriváty $x ekonomika $7 D015774
650    _2
$a lidé $7 D006801
650    _2
$a transplantace ledvin $x škodlivé účinky $7 D016030
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pooperační komplikace $x ekonomika $x prevence a kontrola $7 D011183
650    _2
$a valin $x aplikace a dávkování $x analogy a deriváty $x ekonomika $7 D014633
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kielberger, L $u Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Bouda, Mirko $u Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. $7 xx0330644
700    1_
$a Reischig, T $u Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
773    0_
$w MED00005143 $t Transplant infectious disease $x 1399-3062 $g Roč. 17, č. 3 (2015), s. 334-41
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25824586 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20250402092210 $b ABA008
999    __
$a ok $b bmc $g 1239932 $s 985164
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 17 $c 3 $d 334-41 $e 20150526 $i 1399-3062 $m Transplant infectious disease $n Transpl Infect Dis $x MED00005143
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...